Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Easy zero. Keep dreaming though. There will be no such regulation.
Yes, but this would be years away. FDA approval gives a little confidence to the drug in an equivalent complex submission process.
Dr Jean Pfizer. That is hilarious! Does this count as having Pfizer as a partner?! Lol
I was assuming he meant the quarter starting in July ending in September & Sungen filing subsequent quarter. Sometimes he talks fiscal calendar & others the normal calendar. Hard to keep straight.
Likely excuse. What happens when sales slow? Inventory is elevated.
Sure. Clearly has nothing to do with the declining sales.
Credit need to be given where credit is due. This is the first time in years that I can recall offhand when the stock price did not tank during or after the conference call. However, one data point is not a trend.
I agree here. I could care less about the generics for the most part. The pipeline was what I was most interested in. Good to hear about 1st SunGen filing in couple quarters. I am still uncertain on SequestOx trial. OxyContin ANDA filed this quarter. Pipeline is moving along, but will the FDA play nice?
If Elite has no cash in 4 years, the company better have a new CEO & CFO.
Not that it matters. No live Q&A.
Glad you noticed the inventory as well. Sales flat, inventory goes through the roof. Extremely poor resource management at best. Stinky pinky management deserves to stay on the OTC.
IR will filter out certain questions for Nasrat to respond. This is normal cherry picking. Anything remotely confrontational will not be seen or responded to by the CEO. Typical IR protocol.
After this crappy 10-K, the purpose of the ratchet provision is so much clearer now.
The only news we'll get tomorrow is about Trump. Same as yesterday and day before. No real news until July re: SequestOx.
Same old, same old.
Except that is all Elite is proven they can execute. Not sure I'd call Trimipramine that though. More like a breadcrumb wannabe.
And how are those Epic Oxy sales doing that were supposedly going to be a huge boost to the top and bottomline? I think Trimipramine is bringing in more revenue.
Except the only thing he has proven is that he can make BS. Competitors are the ones laughing.
That is ridiculous. Do you know IR functions? Plus, there are only retail holders. Activist retail holder has no definition for IR.
What was the y/y qtr comparison?
For the Board to approve a 20% bump now makes them look more and more competent each day.
Snup's posts are fun to read. I personally get pissed at the lack of accountability on the missed timelines, flubs and self dealing. That is what ticks me off.
That NASDAQ goal has been pushed back farther & farther. He was counting on SequestOx approval a couple years ago to get there. Didn't happen. His ever increasing dilution will make it much harder now.
I want to see one approval prior to another study. There is too much pipeline without any proof to the tech by the FDA. To say "because the FDA didn't say anything about our tech" means they approve it - is pure garbage by omission. It means nothing. Proof is in the pudding starting this week.
My guess - more of the same - nothing, but more smoke. We will probably hear "how well" the generics are doing again by the CFO along with logistical excuses on shipment timing.
What I am really hoping for is a Trimipramine update. I want to hear about all those dying to get their hands on this one.
How about the self-dealing with Mikah? The more ridiculous non-arms length deals deals the CEO does, the more my confidence erodes. Beyond disgusting waste of resources.
Very true, but I actually believe Nasrat here. It is not uncommon for FDA to do this. I have seen it with other pharmas too.
I believe the other commissioners didn't either, which is why the submission requirements changed for Elite.
I interpret this morning's note that Gottlieb is skeptical of ADT claims, which is why post-marketing studies will be required.
Wow. LOL You are now qualified to be Elite's CFO.
University of Phoenix Online
If they actually have a goal of being on the NASDAQ they need to clean this up by getting a real CFO who understands finance and accounting, and need to implement the appropriate separation of duties and controls.
However, if the company is seeking to be bought out then there is no need to worry about this. This is the direction that I think they are going, for better or for worse.
Accounting error from a couple years ago in misstating revenue was from pure inadequacy. This is more from lack of people infrastructure in not having enough headcount or not knowing who can/can't do what duties.
Because accountability surely isn't important along with adding value and not wasting cash resources. Lol
Of course the company will announce it approved or declined by the FDA as that is a major event and the company is required to do so. No one is arguing the contrary. My comment was to not expect any update at this CC regarding Percocet.
Don't count on it. That update, for better or worse, will be a one-off 8-k.
Please enlighten us of the last time the stock price rose after a conference call? I'll give you a hint: The CEO opens his mouth and the stock does this [fill in the blank].
Milestones have the same impact in 2017 as they do in 2016. There is no change. Revenue is spread over tenure of agreement with Epic. Now If that Epic agreement comes to an end, you can play an accounting trick and have the remaining amount booked as revenue, similar to writing off remaining book depreciation when selling assets. I wouldn't be surprised to see this sleight of hand at some point.
Yes, one or the other.
Multi-million decrease? They are barely doing multi-million on a quarterly basis. That isn't even possible unless all shipments were put on hold for the quarter. Completely unrealistic.
Revenues have consistently increased, but at a significantly decreasing rate. Last quarter barely eeked out a 6% y/y increase. It was the 2nd consecutive quarter blaming timing of shipping. When companies blame timing, they have lost focus on operational & top line improvements.
I would not be surprised to see a revenue decrease compared to last year.
Perhaps the backlogged demand in Trimipramine saved the day? Lol
Another massive 6% spike?